Navigation Links
eResearchTechnology Reports First Quarter 2008 Results
Date:5/5/2008

.1 million, compared to $29.7 million for the

first quarter of 2007;

-- Bookings included seven new Thorough ECG study agreements valued at an

average of slightly greater than $1 million each;

-- The backlog was a record $151.4 million, a net increase of

$11.2 million from December 31, 2007;

-- The cancellation rate was an annualized 15.6% as compared to an

annualized cancellation rate of 15.0% in the first quarter of 2007.

"We are extremely pleased with the first quarter results where we saw record quarterly revenue, transactions, bookings and backlog for eRT," commented Dr. Michael McKelvey, President and CEO of eRT. "We continue to execute very well on our projects. The integration of the CCSS acquisition is proceeding on schedule, and we are meeting with clients to begin the transition process of individual studies. Our services revenue grew by 80.9%, driven by outstanding growth in our core cardiac safety business. Bookings were strong across all phases, but especially in Phase I and Phase III studies. The quarter again demonstrated the leverage in our business model as evidenced by expanding gross margins and net income growth."

The Company reported revenues of $33.7 million for the first quarter of 2008, an increase of 59.7% from $21.1 million in the first quarter of 2007. Net income was $5.7 million for the first quarter of 2008, an increase of 155.6% from $2.2 million for the first quarter of 2007. Diluted net income per share was $0.11 for the first quarter of 2008, up $0.07 from the $0.04 in the first quarter of 2007.

eRT ended the quarter with $48.9 million in cash, cash equivalents and investments, an increase of $2.0 million from $46.9 million at December 31, 2007. Operations generated $7.6 million, which was partially offset by payments to Covance under the terms of the CCSS acquisition.

"Our pipeline of new opportunities is strong, reflecting the continued emphasis on c
'/>"/>

SOURCE eResearchTechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. eResearchTechnology to Present at the Deutsche Bank 33rd Annual Healthcare Conference on May 7th 2008
2. eResearchTechnology, Inc. to Announce 2008 First Quarter Results on May 5, 2008
3. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
4. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
5. eResearchTechnology, Inc. to Announce 2007 Fourth Quarter Results on February 26, 2008
6. eResearchTechnology to Present at the UBS Global Healthcare Services Conference 2008 on February 11th
7. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
8. MannKind Corporation Reports First Quarter Financial Results
9. Verenium Reports Financial Results for the First Quarter 2008
10. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
11. United Therapeutics Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 According to a new market ... - Global Industry Analysis, Size, Share, Growth, Trends and ... is estimated at USD 161,056.5 million in 2014 and ... from 2014 to 2020, to reach an estimated value ... drugs market is witnessing a significant growth due to ...
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... 2011 Operational and Financial Results ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Nov. 11, 2010 StemCyte, Inc., one of the ... companies, is proud to announce that the Company has ... U.S. Internal Revenue Service,s Qualifying Therapeutic Discovery Project (QTDP) ... fewer than 250 employees. The Patient Protection ...
... (Nasdaq: ARAY ), a global leader in the ... to present at the Lazard Capital Markets, Healthcare Conference in ... a.m. ET/7:30 a.m. PT. A live webcast of ... page of the Company,s Web site at http://www.accuray.com . ...
Cached Biology Technology:YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 2YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 3YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 4YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 5YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 6YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 7YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 8YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 9YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 10YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 11YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 12YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 13YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results 14StemCyte Awarded $488,950 for Advanced Therapeutic Applications of Umbilical Cord Blood Stem Cells from the Qualifying Therapeutic Discovery Project (QTDP) 2Accuray Incorporated to Speak at Seventh Annual Lazard Capital Markets' Healthcare Conference 2
(Date:7/24/2014)... Bhavani Iyer, O.D., a low vision specialist at The ... Medical School, has been awarded a grant to help ... with eyeglasses, medication or surgery. , Even with corrective ... at best. However, there are a variety of low ... to help offset their vision loss. , Iyer is ...
(Date:7/24/2014)... experts gathered at NJIT this week for an all-day ... U.S. Environmental Protection Agency (EPA) to dredge toxic sediment ... , The EPA has called the plan, which proposes ... capping sections of the riverbed, one of the largest ... be dredged and disposed off-site. , "We need to ...
(Date:7/24/2014)... To reduce fire hazard in the United States, wildland ... woody shrubs and suppressed trees (ladder fuels). These ... periods of low fire danger in order to dispose ... hazardous air pollutants, managers often cover all or part ... referred to as agricultural plastic, in order to keep ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2Experts Weigh the Pros and Cons of a $1.7 Billion EPA Cleanup Plan for the Passaic River at an NJIT 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... to the growing list of genetic variants that determine ... by Cell Press on December 30 in the ... previously unknown variants associated with height and might provide ... Although environmental variables can impact attained adult height, ...
... large quantities of nitrate-rich fertilizer to realize optimal ... to balance the amount of nitrogen needed for ... leach into ground and surface waters. Increased interest ... to identify genotypes that have a characteristic called ...
... producers have traditionally relied heavily on hand thinning, a ... increasing labor costs and a limited workforce, peach and ... such as string thinners to minimize the need for ... promising results when it was evaluated in four U.S. ...
Cached Biology News:Large-scale analysis identifies new genetic alterations associated with height 2Improving nitrogen use efficiency lessens environmental impact 2Hybrid string blossom thinner tested in peach orchards 2
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... of X-ray crystallography services for structure-based ... to its pharmaceutical and biotechnology clients. ... drug-like fragments to the active sites ... scientists to develop novel, high-affinity inhibitors. ...
...
... monitoring acetylcholinesterase (AChE) activity. This is a ... min), non-radioactive and easy to use assay ... substrate, acetylcholine. A series of coupled enzyme ... into a change in luminescence. Inhibitors of ...
Biology Products: